Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases

Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases

Source: 
Fierce Pharma
snippet: 

Driven by the idiopathic pulmonary fibrosis market, Boehringer Ingelheim’s Ofev finally hit blockbuster sales in 2018. An FDA nod in a rare lung disease, Ofev is targeting even more small indications to add to its portfolio.